Journal of Diabetes review flags baseline age disparities across GLP-1 agonist trials
The analysis examines how enrollment ages differ between incretin trials, a gap that complicates applying results to older patients.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 20:00 ETSource: Journal of diabetes
The wire
- 01Researchers compared baseline age across GLP-1 receptor agonist-based trials and report disparities between study populations.
- 02Clinicians extrapolating incretin trial results to older or younger patients should know the enrolled populations were not age-matched.
- 03The analysis is descriptive; it does not establish how age differences changed efficacy or safety outcomes.
From the source
Read at pubmed.ncbi.nlm.nih.govBaseline Age Disparities Across GLP-1 Receptor Agonist-Based Trials
Journal of diabetes · 2026 Oct · Yang W, Zhao W, Cai X et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42894328/
